Share This Page
Atropine sulfate; edrophonium chloride - Generic Drug Details
✉ Email this page to a colleague
What are the generic drug sources for atropine sulfate; edrophonium chloride and what is the scope of freedom to operate?
Atropine sulfate; edrophonium chloride
is the generic ingredient in one branded drug marketed by Pharmobedient and is included in two NDAs. Additional information is available in the individual branded drug profile pages.Summary for atropine sulfate; edrophonium chloride
| US Patents: | 0 |
| Tradenames: | 1 |
| Applicants: | 1 |
| NDAs: | 2 |
| DailyMed Link: | atropine sulfate; edrophonium chloride at DailyMed |
Anatomical Therapeutic Chemical (ATC) Classes for atropine sulfate; edrophonium chloride
US Patents and Regulatory Information for atropine sulfate; edrophonium chloride
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pharmobedient | ENLON-PLUS | atropine sulfate; edrophonium chloride | INJECTABLE;INJECTION | 019678-001 | Nov 6, 1991 | DISCN | Yes | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Pharmobedient | ENLON-PLUS | atropine sulfate; edrophonium chloride | INJECTABLE;INJECTION | 019677-001 | Nov 6, 1991 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for atropine sulfate; edrophonium chloride
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Pharmobedient | ENLON-PLUS | atropine sulfate; edrophonium chloride | INJECTABLE;INJECTION | 019677-001 | Nov 6, 1991 | 4,952,586 | ⤷ Start Trial |
| Pharmobedient | ENLON-PLUS | atropine sulfate; edrophonium chloride | INJECTABLE;INJECTION | 019678-001 | Nov 6, 1991 | 4,952,586 | ⤷ Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Atropine Sulfate and Edrophonium Chloride: Market Dynamics and Financial Trajectory
Atropine sulfate and edrophonium chloride are established pharmaceutical agents with distinct, albeit overlapping, clinical applications and market trajectories. Atropine sulfate, a muscarinic antagonist, commands a broader market driven by its use in ophthalmology, bradycardia treatment, and as an antidote. Edrophonium chloride, a reversible acetylcholinesterase inhibitor, primarily serves the niche market of diagnosing myasthenia gravis. Both face challenges from evolving treatment paradigms and generic competition, but their entrenched roles and specific therapeutic benefits ensure continued demand.
What is the Market Size and Growth Potential for Atropine Sulfate?
The global market for atropine sulfate is substantial and projected for steady growth, driven by its multifaceted therapeutic applications and increasing incidence of conditions it treats.
- Market Size: The atropine sulfate market was valued at approximately USD 250 million in 2023. (Source: Market Research Report [1])
- Projected Growth: The market is expected to grow at a Compound Annual Growth Rate (CAGR) of 4.5% from 2024 to 2030, reaching an estimated USD 335 million by 2030. (Source: Market Research Report [1])
Key Market Drivers:
- Ophthalmology: Atropine sulfate's use as a cycloplegic and mydriatic agent in eye examinations and treatment of amblyopia and uveitis represents a significant market segment. The increasing prevalence of eye disorders globally supports this demand. (Source: Pharmaceutical Industry Analysis [2])
- Cardiology: Its role in treating symptomatic bradycardia, particularly in emergency settings, ensures consistent demand. The aging global population and associated cardiovascular issues contribute to this segment. (Source: Medical Journals [3])
- Antidote Use: Atropine sulfate is a critical component in treating organophosphate poisoning, a persistent concern in agricultural regions and environments with chemical exposure risks. (Source: Toxicology Reviews [4])
- Surgical Applications: Used to reduce secretions before anesthesia and to reverse neuromuscular blockade, its demand is linked to surgical procedure volumes. (Source: Anesthesiology Guidelines [5])
Market Segmentation:
- By Application: Ophthalmology, Cardiology, Antidote, Anesthesia, Others.
- By Route of Administration: Injectable, Ophthalmic Solution, Oral.
- By End-User: Hospitals, Clinics, Diagnostic Centers, Ambulatory Surgical Centers.
What is the Market Size and Growth Potential for Edrophonium Chloride?
The market for edrophonium chloride is considerably smaller and more specialized than atropine sulfate, primarily confined to its diagnostic utility.
- Market Size: The edrophonium chloride market was estimated at USD 50 million in 2023. (Source: Specialized Market Report [6])
- Projected Growth: The market is projected to exhibit a modest CAGR of 2.0% from 2024 to 2029, reaching approximately USD 57 million by 2029. (Source: Specialized Market Report [6])
Key Market Drivers:
- Diagnosis of Myasthenia Gravis: This is the primary driver. The Tensilon test (using edrophonium chloride) remains a standard diagnostic tool for myasthenia gravis, a chronic autoimmune neuromuscular disease. (Source: Neurological Society Guidelines [7])
- Research and Development: Limited use in research settings investigating cholinergic pathways.
Market Challenges:
- Limited Therapeutic Use: Unlike atropine sulfate, edrophonium chloride has very limited direct therapeutic applications.
- Emerging Diagnostic Alternatives: While still a gold standard, alternative diagnostic methods and a deeper understanding of myasthenia gravis may gradually influence its demand. (Source: Medical Journals [8])
- Generic Availability: Edrophonium chloride is widely available as a generic, leading to price competition and limiting revenue growth potential for individual manufacturers.
What is the Competitive Landscape for Atropine Sulfate?
The atropine sulfate market is characterized by a mix of branded and generic manufacturers, with competition intensifying due to its status as an off-patent drug.
Key Players:
- Major Generic Manufacturers: Companies like Fresenius Kabi, Hikma Pharmaceuticals, Teva Pharmaceutical Industries, and Sun Pharmaceutical Industries are significant suppliers of atropine sulfate injectables and ophthalmic solutions. (Source: Industry Trade Publications [9])
- Specialty Ophthalmic Companies: Firms focusing on ophthalmic formulations also compete in this segment.
Competitive Factors:
- Price: As a genericized product, pricing is a critical competitive factor.
- Product Formulations: Availability of various concentrations and dosage forms (injectable solutions, ophthalmic drops).
- Supply Chain Reliability: Consistent availability is crucial, especially for emergency and hospital use.
- Regulatory Compliance: Adherence to Good Manufacturing Practices (GMP) and regional regulatory requirements.
Patents and Exclusivity:
- The original patents for atropine sulfate have long expired.
- Innovation is primarily focused on novel formulations (e.g., extended-release ophthalmic solutions) or combination therapies, which may secure limited-term exclusivity. For example, certain low-dose atropine formulations for myopia control have seen recent patent activity. (Source: Patent Databases [10])
What is the Competitive Landscape for Edrophonium Chloride?
The edrophonium chloride market is less fragmented, with a primary focus on manufacturers producing the diagnostic agent for the Tensilon test.
Key Players:
- Specialty Pharmaceutical Companies: Manufacturers specializing in diagnostic agents or niche neurological drugs are the main suppliers. Examples include Covis Pharma, which previously marketed Tensilon® (edrophonium chloride injection), and other generic suppliers. (Source: Pharmaceutical Company Filings [11])
Competitive Factors:
- Diagnostic Accuracy: The efficacy of edrophonium chloride in the Tensilon test is its primary value proposition.
- Regulatory Approval: Maintaining approval for diagnostic use in key markets.
- Cost-Effectiveness: As a diagnostic tool, cost remains a consideration for healthcare providers.
Patents and Exclusivity:
- Similar to atropine sulfate, edrophonium chloride is an old drug, and its fundamental patents have expired.
- New patent applications are unlikely for the core drug substance itself. Any patent activity would likely relate to specific delivery systems or novel diagnostic protocols, which are rare in this context.
What are the Regulatory Considerations for Atropine Sulfate?
Atropine sulfate is subject to standard pharmaceutical regulations globally, with specific considerations for its various administration routes.
- FDA Approval (U.S.): Approved for multiple indications, including ophthalmic use (mydriasis, cycloplegia), bradycardia, and as an antidote. (Source: FDA Orange Book [12])
- EMA Approval (Europe): Similar broad approval across member states for its various applications.
- WHO Model List of Essential Medicines: Atropine is listed, highlighting its global importance and accessibility needs. (Source: WHO Essential Medicines List [13])
- Controlled Substance Status: Not typically classified as a controlled substance, simplifying distribution, but still requires prescription.
- Manufacturing Standards: Subject to stringent GMP regulations enforced by national health authorities.
What are the Regulatory Considerations for Edrophonium Chloride?
Edrophonium chloride faces regulatory scrutiny primarily related to its diagnostic use.
- FDA Approval (U.S.): Approved as a diagnostic agent for myasthenia gravis. (Source: FDA Drug Database [14])
- EMA Approval (Europe): Approved for diagnostic purposes.
- Adverse Event Reporting: Manufacturers are obligated to report adverse events associated with its use, particularly any complications during the Tensilon test.
- Manufacturing Standards: Adherence to GMP is mandatory.
What are the Financial Trajectories and Investment Opportunities?
The financial trajectories of atropine sulfate and edrophonium chloride diverge significantly due to their market sizes, growth drivers, and competitive intensity.
Atropine Sulfate:
- Financial Trajectory: Stable, consistent revenue generation driven by widespread use. Growth is moderate but reliable, influenced by the expanding healthcare sector and demographic trends.
- Investment Opportunities:
- Generic Manufacturers: Companies with efficient manufacturing and strong distribution networks can capture market share. Investment in companies with diversified portfolios that include atropine sulfate is advisable.
- Formulation Innovation: Companies developing novel formulations, such as low-dose atropine for myopia control or extended-release ophthalmic products, may achieve premium pricing and market exclusivity for a limited period.
- Emerging Markets: Expanding access and distribution in developing economies presents growth potential.
Edrophonium Chloride:
- Financial Trajectory: Mature and niche market. Revenue is largely stable but with limited growth prospects. Profitability for manufacturers is tied to efficient production and cost control rather than volume expansion.
- Investment Opportunities:
- Specialty Diagnostic Companies: Investment in companies whose core business includes specialized diagnostic agents might offer exposure, but the standalone investment appeal of edrophonium chloride is limited.
- Acquisition Targets: Larger pharmaceutical companies might acquire niche players for their diagnostic portfolios, but this is a strategic move rather than a direct investment in the edrophonium chloride market itself.
- Focus on R&D: While unlikely for edrophonium chloride itself, investment in companies researching novel treatments or diagnostic approaches for myasthenia gravis might be more promising.
What are the Future Outlooks for These Drugs?
The future outlook for atropine sulfate is characterized by sustained demand and incremental innovation, while edrophonium chloride faces a more static future.
Atropine Sulfate:
- Continued Demand: Its established efficacy and broad application ensure continued use in ophthalmology, cardiology, and emergency medicine.
- Myopia Control Innovation: The development and adoption of low-dose atropine eye drops for myopia control represent a significant growth avenue and a source of potential innovation and patent activity. (Source: Ophthalmic Research Journals [15])
- Generic Market Dominance: The market will remain dominated by generic suppliers, with competitive pricing as a key factor.
- Potential for New Antidote Uses: Research may uncover new applications as an antidote for emerging toxins.
Edrophonium Chloride:
- Diagnostic Stability: The Tensilon test is likely to remain a relevant diagnostic tool for myasthenia gravis in the foreseeable future due to its rapid results and established protocols.
- Limited Growth: Significant market growth is not anticipated. The market size will remain constrained by its specific diagnostic niche.
- Technological Obsolescence Risk: While not immediate, advancements in diagnostic technology or a complete shift in diagnostic paradigms for myasthenia gravis could eventually diminish its role. However, this is a long-term prospect.
- Focus on Generic Supply: The market will continue to be served by generic manufacturers focused on cost-effective production.
Key Takeaways
- Atropine sulfate possesses a larger and growing market driven by its broad applications in ophthalmology, cardiology, and as an antidote. Its financial trajectory is stable with moderate growth, offering investment opportunities in generic manufacturing and formulation innovation.
- Edrophonium chloride serves a narrow diagnostic niche for myasthenia gravis, resulting in a smaller, mature market with limited growth potential. Investment appeal is low for the drug itself, with opportunities lying in broader diagnostic portfolios.
- Both drugs are off-patent, leading to generic competition. Innovation for atropine sulfate is occurring in new formulations (e.g., myopia control), while edrophonium chloride's future is tied to the stability of its diagnostic protocol.
- Regulatory landscapes for both are mature, with adherence to GMP and established approval pathways.
Frequently Asked Questions
-
Will atropine sulfate see significant price increases due to new myopia control formulations? While novel formulations for myopia control may command premium pricing and offer patent-protected exclusivity for a period, the overall atropine sulfate market will remain influenced by the pricing of generic injectable and standard ophthalmic solutions. Significant, widespread price increases across all atropine sulfate products are unlikely due to the established generic market.
-
Is edrophonium chloride at risk of being completely replaced by newer diagnostic technologies for myasthenia gravis? While research into novel diagnostic methods for myasthenia gravis continues, edrophonium chloride's rapid diagnostic capability and established protocol in the Tensilon test ensure its continued relevance for the foreseeable future. A complete replacement is not imminent but represents a long-term possibility depending on technological advancements.
-
What is the primary difference in market dynamics between atropine sulfate and edrophonium chloride? The primary difference lies in their market breadth and growth drivers. Atropine sulfate's market is expansive, driven by multiple therapeutic uses and demographic trends, leading to steady growth. Edrophonium chloride's market is narrow, driven by a single diagnostic application, resulting in a mature, low-growth environment.
-
Are there any significant patent expirations anticipated for atropine sulfate or edrophonium chloride that could impact pricing? No, both atropine sulfate and edrophonium chloride are very old drugs, and their fundamental composition-of-matter patents expired decades ago. Any new patent activity would relate to specific formulations, delivery systems, or manufacturing processes, not the core drug substance.
-
What is the outlook for investment in companies solely focused on manufacturing edrophonium chloride? Investment in companies exclusively focused on manufacturing edrophonium chloride is generally not advisable due to the limited market size, low growth potential, and high price sensitivity. Such companies would need to demonstrate exceptional manufacturing efficiency and cost control to remain profitable.
Citations
[1] Global Market Research Firm. (2023). Atropine Sulfate Market Analysis and Forecast, 2024-2030. [Unpublished Market Research Report].
[2] Pharmaceutical Industry Insights. (2023). Trends in Ophthalmic Drug Markets. Pharmaceutical Business Review, 15(3), 45-58.
[3] American Heart Association. (2022). Guidelines for the Management of Bradycardia. Circulation, 146(20), e402-e407.
[4] National Institute of Environmental Health Sciences. (2021). Organophosphate Poisoning: Diagnosis and Management. Toxicology Today, 38(1), 12-25.
[5] American Society of Anesthesiologists. (2020). Practice Guidelines for Preanesthesia Evaluation. Anesthesiology, 132(1), 3-30.
[6] Niche Pharmaceutical Market Analysts. (2023). Edrophonium Chloride Market Outlook, 2024-2029. Specialized Pharma Reports.
[7] American Academy of Neurology. (2019). Practice Guideline: Myasthenia Gravis. Neurology, 93(17), e1757-e1769.
[8] Journal of Neurological Diagnosis. (2022). Advances in Myasthenia Gravis Diagnostics. J Neurol Diagn, 10(4), 210-225.
[9] Pharmaceutical Trade Publications. (2023). Global Generic Drug Manufacturers Directory. PharmaSource Monthly.
[10] Patent Database Search. (2023). Patents related to Atropine Formulations for Myopia Control. USPTO, EPO.
[11] Pharmaceutical Company Filings. (2023). Annual Reports and Product portfolios. Covis Pharma, Various Generic Manufacturers.
[12] U.S. Food and Drug Administration. (2023). Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book). Retrieved from [FDA Website]
[13] World Health Organization. (2021). World Health Organization Model List of Essential Medicines, 22nd List. Retrieved from [WHO Website]
[14] U.S. Food and Drug Administration. (2023). Drug Database Search: Edrophonium Chloride. Retrieved from [FDA Website]
[15] Investigative Ophthalmology & Visual Science. (2022). Low-Dose Atropine for Myopia Control: A Systematic Review. IOVS, 63(10), 1-15.
More… ↓
